The FDA announced on Friday (5/8) of its approval for Eli Lily’s Retevmo, a drug which treats three kinds of tumors associated with lung and thyroid cancer: non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers. This comes as the first drug approved for adult patients with this genetic mutation, as well as pediatric patients over 12 with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory if appropriate. Since the FDA’s approval, Eli Lilly has moved to have the drugs available for patients within the week for specialty pharmacies. 

Read more here

More on: